Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Conditions: Advaced Solid Tumors; Melanoma Intervention: Biological: AK104 Sponsors: Akeso; Akeso Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials